Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase I/II Clinical Trial for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated announced that the US FDA has lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia.